Celltrion USA announced that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective April 4, 2024 provides ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary serving 21.9 Million insured lives. Express Scripts provides plan participants such as Health Plans of the PBM the ability to add ZYMFENTRA™ (infliximab-dyyb) to their formularies.

"This agreement opens up an important pathway for access to treatment for millions of patients with chronic diseases," said Francine Galante, Vice President of Market Access at Celltrion USA. "We will continue to work with providers, patients and physicians to build upon our mission of developing transformational therapies that meet the needs of our patients living with chronic debilitating pain."

Celltrion's ZYMFENTRA, the first and only FDA-approved subcutaneous infliximab is now commercially available in the U.S.

The company continues to engage with national and regional health plans, as well as Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs), to communicate the value of its FDA-approved therapies including ZYMFENTRA for patients with autoimmune disease and to secure broad coverage.